$NTRA

On September 14-16, 2026, insiders made notable transactions: MNR's CEO bought $2M in units, GLP's GP bought $768K in units, PLNT's director bought $119K in shares, BDN's CEO bought $100K in shares, and ARDC's 10% owner bought $6M in preferred shares. Meanwhile, insiders sold shares in Natera, Chime, Sandisk, and Reddit, with transactions ranging from $10M to $51M. InvestingPro analysis provided valuation insights for these companies.

Natera (NTRA) shares hit a 52-week high, up 7.66% this month, driven by record volumes of its Signatera cancer test. The company reported sequential unit additions of 34,000 and raised its average selling price to $1,275. Guggenheim raised its price target to $360 with a Buy rating. Natera's market cap is near $49.2 billion.

Rabinowitz Matthew (EXECUTIVE CHAIRMAN) sold 2,000 indirectly-held shares of Natera, Inc. (NTRA) at $350.01 ($0.70M total) on 2026-09-15 under a Rule 10b5-1 trading plan.

Rabinowitz Matthew (EXECUTIVE CHAIRMAN) sold 100,000 shares of Natera, Inc. (NTRA) at an average of $340.97 ($328.09–$351.24, $34.10M total) across 28 trades over 2026-09-14 to 2026-09-15 under a Rule 10b5-1 trading plan.

ARK Invest, led by Cathie Wood, sold shares in multiple crypto-linked holdings, including ARKB, COIN, CRCL, and BMNR. The firm trimmed over 1.5% of its Bitcoin ETF (ARKB) positions. Bitcoin's price fell below $77,000, and retail sentiment remained bearish. Other tech stocks like AMZN, AMD, and SHOP were also reduced.

Rabinowitz Matthew (EXECUTIVE CHAIRMAN) sold 50,000 shares of Natera, Inc. (NTRA) at an average of $327.97 ($325.01–$329.62, $16.40M total) across 6 trades on 2026-09-11 under a Rule 10b5-1 trading plan.

Natera (NTRA) reported Q2 revenue of $752.8M, up 37.7% YoY, and raised its 2026 revenue forecast. Jim Cramer called it a promising precision medicine platform but advised waiting for a pullback due to valuation concerns. The company faces competition and regulatory risks, with a net loss of $67M in Q2.

Natera Inc (NTRA) CEO Steven Chapman sold 1,698 shares at $320.99 each on September 1, 2026, per SEC filing. He now owns 98,199 shares. Over the past year, he sold 433,410 shares with no purchases. Natera's stock is trading at $320.99, with a market cap of $47.23 billion, but is considered significantly overvalued by GuruFocus.

Natera, Inc. (NASDAQ:NTRA) President Solomon Moshkevich sold 18,160 shares totaling $5.92 million over two days. Shares were sold at prices ranging from $319.7582 to $326.894, with sales conducted under a Rule 10b5-1 trading plan. Natera's stock is near its 52-week high, up 97% over the past year, and reported strong Q2 revenue of $753 million, exceeding expectations. The company raised its full-year revenue guidance, citing record test volumes and improved margins. According to InvestingPro, th

Moshkevich Solomon (PRESIDENT, CLINICALDIAGNOSTICS) sold 18,160 shares of Natera, Inc. (NTRA) at an average of $325.88 ($319.76–$326.89, $5.92M total) across 4 trades over 2026-09-01 to 2026-09-02 under a Rule 10b5-1 trading plan.